Scolaris Content Display Scolaris Content Display

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 1 Six minute walk.
Figuras y tablas -
Analysis 1.1

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 1 Six minute walk.

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 2 Number of patients who improved their classification (WHO or NYHA functional class).
Figuras y tablas -
Analysis 1.2

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 2 Number of patients who improved their classification (WHO or NYHA functional class).

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 3 Symptoms.
Figuras y tablas -
Analysis 1.3

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 3 Symptoms.

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 4 Mortality.
Figuras y tablas -
Analysis 1.4

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 4 Mortality.

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 5 Pulmonary artery pressure (change from baseline).
Figuras y tablas -
Analysis 1.5

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 5 Pulmonary artery pressure (change from baseline).

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 6 Pulmonary vascular resistance (change from baseline).
Figuras y tablas -
Analysis 1.6

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 6 Pulmonary vascular resistance (change from baseline).

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 7 Cardiac Index (change from baseline).
Figuras y tablas -
Analysis 1.7

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 7 Cardiac Index (change from baseline).

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 8 Hepatic toxicity.
Figuras y tablas -
Analysis 1.8

Comparison 1 Endothelin receptor antagonists versus placebo, Outcome 8 Hepatic toxicity.

Comparison 1. Endothelin receptor antagonists versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Six minute walk Show forest plot

2

Metres (Fixed, 95% CI)

46.24 [23.96, 68.53]

2 Number of patients who improved their classification (WHO or NYHA functional class) Show forest plot

3

423

Risk Ratio (M‐H, Fixed, 95% CI)

1.65 [1.17, 2.32]

2.1 Nonselective ERAs

2

245

Risk Ratio (M‐H, Fixed, 95% CI)

1.52 [1.02, 2.26]

2.2 Selective ERAs

1

178

Risk Ratio (M‐H, Fixed, 95% CI)

1.98 [1.02, 3.84]

3 Symptoms Show forest plot

2

Borg dyspnoea score (Random, 95% CI)

‐0.83 [‐1.65, ‐0.01]

4 Mortality Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

5 Pulmonary artery pressure (change from baseline) Show forest plot

3

208

Mean Difference (IV, Fixed, 95% CI)

‐4.36 [‐6.77, ‐1.94]

5.1 Nonselective ERAs

1

30

Mean Difference (IV, Fixed, 95% CI)

‐6.70 [‐12.67, ‐0.73]

5.2 Selective ERAs

2

178

Mean Difference (IV, Fixed, 95% CI)

‐3.90 [‐6.54, ‐1.25]

6 Pulmonary vascular resistance (change from baseline) Show forest plot

3

208

Mean Difference (IV, Fixed, 95% CI)

‐286.73 [‐369.10, ‐204.36]

6.1 Nonselective ERAs

1

30

Mean Difference (IV, Fixed, 95% CI)

‐414.0 [‐595.77, ‐232.23]

6.2 Selective ERAs

2

178

Mean Difference (IV, Fixed, 95% CI)

‐253.84 [‐346.24, ‐161.44]

7 Cardiac Index (change from baseline) Show forest plot

4

289

Mean Difference (IV, Random, 95% CI)

0.51 [0.22, 0.81]

7.1 Nonselective ERAs

2

111

Mean Difference (IV, Random, 95% CI)

0.68 [0.06, 1.30]

7.2 Selective ERAs

2

178

Mean Difference (IV, Random, 95% CI)

0.35 [0.18, 0.52]

8 Hepatic toxicity Show forest plot

3

422

Odds Ratio (M‐H, Random, 95% CI)

1.62 [0.57, 4.55]

8.1 Nonselective ERAs

2

245

Odds Ratio (M‐H, Random, 95% CI)

1.45 [0.22, 9.71]

8.2 Selective ERAs

1

177

Odds Ratio (M‐H, Random, 95% CI)

1.53 [0.30, 7.81]

Figuras y tablas -
Comparison 1. Endothelin receptor antagonists versus placebo